Summary.-The effector arm of antibody-dependent cellular cytotoxicity (ADCC) was evaluated using 5lCr-labelled chicken erythrocytes as targets in BALB/c mice transplanted with the Moloney sarcoma virus-induced tumours T-MSV and MS2, and in C57BL/6 mice transplanted with the chemically induced FS6 sarcoma, Lewis lung carcinoma and B16 melanoma. Tumour-bearing animals showed higher levels of ADCC than normal mice, a stimulation confirmed in MS2-bearing mice, using SL2 lymphoma cells as targets in a cytostasis assay.
IT is now well established that lymphoid cells can express cytotoxic activity for target cells in vitro in the presence of specific antibody (MacLennan, 1972; Perlmann, Perlmann and AWigzell, 1972) .
Effector cells involved in antibody-dependent cellular cytotoxicity (ADCC), hereafter referred to as K cells, appear to be heterogenous, both macrophages andc nonphagocytic cells having been reported to express cytotoxicity for antibody-coated target cells (Greenberg et al., 1975b; Zighelboim, Bonavida and Fahey, 1973; Sanderson and Taylor, 1976; Evans and Alexander, 1 976; Jolley, Boyle and Ormerod, 1976) .
The role played by ADCC in tumourbearing animals is still not entirely clear. Serum collected from rodents with chemical or virus-induced tumours can render normal. lymphoid cells cytotoxic for tumour target cells or increase the cytotoxicity of immune lymphocytes (Pollack, 1973; Ortiz de Landazuri, Kedar and Fahey, 1974; Basham and Currie, 1974) . Moreover, passive transfer of cell-dependent antibodies results in significant antitumoral effects in vivo, thus suggesting that ADCC could represent an important antitumoral effector mechanism (Hersey, 1973; Zighelboim, Bonavida and Fahey, 1974) .
Little effort has been made to analyse possible modifications of K-cell activity in tumour-bearing animals. In a recent report, mice bearing an immunogenic chemically induced sarcoma were found to have increased ADCC effector capacity (Ghaffar, Calder and Irvine, 1976 Animals.-Male C57BL/6 and BALB/c mice (6-8 weeks old) were obtained from Charles River, Calco, Italy.
Tumours.-MSV-induced sarcomas T-MSV and MS2 have previously been described in detail (Giuliani, Casazza and Di Marco, 1974; Di Marco et al., 1976; Giuliani et al., 1977 Evans and Alexander, 1977) and has a macrophage content of 3900.
Lewis lung carcinoma (3LL) and B16 melanoma, both of spontaneous origin (Geran et al., 1972) , were maintained in syngeneic C57BL/6 mice by i.m. transfer of 2 x 105 tumour cells. Both tumours spontaneously metastasize to the lung and are poorly immunogenic, as assessed by concomitant immunity experiments performed as previously described (Giuliani et al., 1974) . The two tumours have a macrophage content of~2 % Spleen cells.-Spleens were minced with scissors in minimal essential medium (MEM), and resuspended with a Pasteur pipette. After washing twice with MEM, the cells w-ere resuspended in RPMI 1640 medium (Gibco Biocult, Glasgow, Scotland) supplemented with 10% foetal bovine serum (growth medium). To remove phagocyticadherent cells, splenocyte preparations were exposed to carbonyl iron (10 mg/107 cells/ml) as described by Lundgren, Zukoski and Moller (1968) .
After this procedure, the number of phagocytic cells was below 10%, as asse,sed
by Neutral Red uptake. The effectiveness of phagocyte removal was additionally checked as described by Bennett (1966) and, after 5 days of culturing 2-5 x 106 spleen cells in plastic Petri dishes (Cat. No. 25000, Corning, USA), no mature macrophages could be detected morphologically in Giemsa-stained preparations. Finally, in agreement with previous data (Kirchner, Holden and Herberman, 1975) , phagocyte removal by this method also resulted in the disappearance of Corynebacterium parvum-induced spleen macrophage cytotoxicity against lymphoma cells, thus providing a functional demonstration of phagocyte removal. ADCC assay.-ADCC effector cell activity was measured using chicken erythrocytes (CRBC) as targets, as recently described in detail (Tagliabue et al., 1977) . Briefly, 5 x 104 51Cr-labelled CRBC were mixed in plastic tubes wvith splenocytes employing a range (from 5: 1 to 90: 1) of attacker: target-cell (A: T) ratios and with an optimal dilution of mouse anti-CRBC serum. Tubes were incubated for 270 min at 37°C in humidified air with 5Qo CO2 and the percentage of specific cytotoxicity was calculated according to the formula: 00 51Cr release with antibody and spleen cells (Mantovani, 1977 Fig. 1 shows a typical experiment in which K-cell activity was evaluated in BALB/c mice 2 weeks after implantation of 106 cells of the T-MSV and MS2 sarcomas. Splenocytes obtained from tumour-bearing mice were significantly (P < 0-01) more effective in lysing antibody-coated CRBC than normal spleen cells, the number of lymphoid cells required to obtain 5000 lysis being 35, 12 and 7 x 105 for normal, MS2 and T-MSV-transplanted animals respectively.
The kinetics of K-cell activation in these tumour systems is presented in Fig. 2(a) from T-MSV-inoculated animals appeared somewhat more effective than splenocytes from MS2-bearing mice, except on Day 28. when cytotoxicity was similar in animals from both groups.
Results presented in Fig. 1 and 2(a) were obtained using a 4-h 5lCr-release assay, but similar stimulation of ADCC was detectable in tumour-bearing animals using a 24-h incubation.
In order to obtain a measure of total spleen ADCC-effector capacity, the LU50 values were related to spleen cell counts, which were markedly increased in tumourbearing mice (Fig. 2(b) and (c) transplanted with the FS6 sarcoma, the 3LL carcinoma or the B16 melanoma. Activity was assayed 2 weeks after tumour implantation, using CRBC as targets.
these conditions, antibody-induced cellmediated tumour-cell cytostasis was readily observable, thus confirming that inhibition of tumour-cell DNA synthesis can represent a more sensitive indicator of ADCC than lysis of tumour target cells (Greenberg, Shen and Medley, 1 975a; Evans and Alexander, 1976) . Spleen cells from MS2-transplanted mice were employed as attacker cells in these experiments, because they did not nonspecifically inhibit growth and DNA synthesis of tumour cells, as opposed to lymphoid cells from T-MSV sarcoma-bearing mice (unpublished observations). As shown in Fig. 3 , splenocytes collected from MS2 transplanted mice were significantly more inhibitory than normal BALB/c spleen cells of SL2 lymphoma DNA synthesis in the presence of specific alloantibody.
Stimulation of ADCC in cancer-bearing hosts was confirmed in C57BL/6 mice transplanted with FS6, 3LL and B16 Fig. 4 (Ghaffar et al., 1976) (Giuliani et al., 1973) . Effector cells responsible for simulation of ADCC in tumour-bearing mice were not positively identified in this study. Both macrophages and non-adherent non-phagocytic cells can show ADCC against tumour cells and CRBC (Zighelboim et al., 1973; Greenberg et al., 1.975b; Jolley et al., 1976; Sanderson and Taylor, 1976 ; Evans and Alexander, 1]976). Since, after removal of phagocytic-adherent cells by carbonyl iron, spleen cells from tuLmour-bearing mice were still more cytotoxic than phagocyte-deprived normal splenocytes for antibody-coated CRBC, it is suggested that mature phagocytes do not account for the increased K-cell activity detected in tumour bearers.
The biological mechanisms responsible for activation of the cellular arm of ADCC in tumour-bearing animals are still unclear. K-cell stimulation was detectable in both immunogenic and poorly immunogenic tumours, although significantly higher levels of ADCC-effector function were observed in mice bearing immunogenic nonmetastasizing neoplasms. Thus tumour immunogenicity could represent an imporant determinant of the degree of K-cell activation in tumourbearing mice. In view of the available evidence that ADCC may be one mechanism in the control of tumour growth (Pollack, 1973; Ortiz de Landazuri et al., 1974; Basham and Currie, 1974; Hersey, 1937; Zighelboim et al., 1974) and of the finding reported here, that mice bearing an immunogenic nonmetastasizing MSV-induced sarcoma show higher levels of K-cell activity than animals inoculated with metastasizing MSV-induced neoplasms, it is tempting to speculate that the degree of K-cell activation may play a role in determining the biological behaviour of experimental tumours.
The observation that tumour-bearing animals show increased K-cell effector capacity apparently contrasts with the depression of ADCC previously reported in cancer patients (Ting and Terasaki, 1974) . However, the significance of this discrepancy appears doubtful, since little information was given in the clinical study concerning the therapeutic protocols employed, and it is known that surgery, chemotherapy and radiotherapy can inhibit K-cell activity (Campbell et al., 1976; Vose and Moudgil, 1976; Purves and Berenbaum, 1975) . ADCCeffector function in cancer patients is currently being re-evaluated in this laboratory.
